FDA Approves Medexus ' s Supplemental Biologics License Application for Ixinity to Treat Hemophilia B in Pediatric Patients

Toronto, Ontario and Chicago, Illinois-- March 26, 2024 - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently approved Medexus ' s supplemental Biologics License Application (sBLA)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news